ReportsandReports announce it will
carry The Cancer Market Outlook To 2014: Competitive landscape, market size,
pipeline analysis and growth opportunities Market Research Report in its
Store.
Browse the complete Report on:
http://www.reportsandreports.com/market-reports/the-cancer-market-outlook-to-2
014-competitive-landscape-market-/
In the current decade, oncology has been one of the most important growth
segments among the pharmaceutical markets with a major focus on targeted
agents (drug treatments developed to preferentially target those signaling
pathways that are disregulated in tumors). Most innovation in oncology over
the past 10 years has been driven by scientific advances, particularly in
genomics, transcriptomics and proteomics.
In the current environment, the successful oncology players of the future
will be those that can anticipate protocol evolution and design the most
relevant clinical trials. In recent years, biotech companies have fuelled
innovation in oncology more than ever before. Partnering with biotech
companies is a key (but expensive) source of innovation for many pharma
companies as approximately 75% of phase II, III and pre-registration
innovative drugs are of biotech origin.
At $47.7bn, cancer is one of the largest, fastest growing markets in the
pharmaceutical industry. However, pricing risk remains the key investment
concern in oncology. The key concern, however, is not price erosion driven by
competitive forces, but price cuts imposed by payors irrespective of the fact
that such unilateral price cuts by payors have never occurred in any of the
major developed markets and would surely jeopardize the premise on which the
entire biopharmaceutical industry has been built.